NE BUSINESS BUREAU
AHMEDABAD, SEP 17
City-based drug major Cadila Pharmaceuticals on Friday announced that it has received the first overseas approval for its Covid drug Sepsivac from the Philippine’s Food and Drug Administration (FDA), a release said.
Sepsivac received its first overseas approval in Philippines on Wednesday. Philippines FDA, looking into efficacy and safety of the product in Covid treatment, allowed the special importation of the Sepsivac on compassionate grounds, which shall strengthen the fight against Covid, the statement added.
Cadila Pharmaceuticals’ Sepsivac can help in improving the health of a person affected with Covid-19 which is associated with respiratory complications, like cytokine storm and sepsis. This can effectively reduce the negative side effects of the virus. This will pave way for Sepsivac to become a Global Brand with Global Approval by a difference in treatment of Covid.
“Cadila marketing and formulations teams coordinated with authorities to arrange multiple webinars. KOLs from India shared their clinical experience of Sepsivac with Philippines HCPs. The Cadila Pharmaceuticals team worked under the guidance of Dr. Bakulesh Khamar, Executive Director – Research & Development, Dr Manjul Joshipura, Senior Vice President, Innovations and New Products, and Mahidhwaj Sisodia, EVP- International Formulations Business, which paved way for the first overseas approval of Sepsivac,” a senior company official said.
